No Broad Autism Approval for Leucovorin, Despite FDA Commissioner’s Prior Suggestions

The Food and Drug Administration on March 10 changed the approval for a version of the prescription drug leucovorin to include people with a very rare genetic condition. FDA Commissioner Dr. Marty Makary had previously implied that the drug’s new label would cover a much broader group of people with autism, saying that “hundreds of thousands of kids” would benefit. The post No Broad Autism Approval for Leucovorin, Despite FDA Commissioner’s Prior Suggestions appeared first on FactCheck.org.